TAUVID

This brand name is authorized in Lithuania, United States

Active ingredients

The drug TAUVID contains one active pharmaceutical ingredient (API):

1 Flortaucipir ¹⁸F UNII T1JP1KYU9O - FLORTAUCIPIR F-18

Flortaucipir ¹⁸F binds to aggregated tau protein. In the brains of patients with Alzheimer’s disease (AD), tau aggregates combine to form NFTs, one of two components required for the neuropathological diagnosis of AD. Flortaucipir ¹⁸F is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs).

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TAUVID Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V09AX07		V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AX Other central nervous system diagnostic radiopharmaceuticals
Discover more medicines within V09AX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1100952, 1100953
Country: US	FDA, National Drug Code	Identifier(s): 0002-1210